guanfacine has been researched along with Hyperactivity, Motor in 4 studies
Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Four guanfacine-treated subjects (13." | 6.80 | Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. ( Cowen, J; Deng, Y; Dziura, J; King, BH; Loo, S; McCracken, JT; McDougle, CJ; Minjarez, M; Mullett, J; Page, C; Politte, L; Rockhill, C; Sanders, R; Scahill, L; Shah, B; Ward, D, 2015) |
| "Four guanfacine-treated subjects (13." | 2.80 | Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. ( Cowen, J; Deng, Y; Dziura, J; King, BH; Loo, S; McCracken, JT; McDougle, CJ; Minjarez, M; Mullett, J; Page, C; Politte, L; Rockhill, C; Sanders, R; Scahill, L; Shah, B; Ward, D, 2015) |
| "Guanfacine is an important medication option in very young children; however, there is a significant pharmacologic "information gap," and further research is needed to help establish appropriate, safe, and effective dosing of guanfacine in this population." | 2.53 | Clinical and Pharmacologic Considerations for Guanfacine Use in Very Young Children. ( Black, BT; Jones, BL; Kearns, GL; Soden, SE, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Scahill, L | 1 |
| McCracken, JT | 1 |
| King, BH | 1 |
| Rockhill, C | 1 |
| Shah, B | 1 |
| Politte, L | 1 |
| Sanders, R | 1 |
| Minjarez, M | 1 |
| Cowen, J | 1 |
| Mullett, J | 1 |
| Page, C | 1 |
| Ward, D | 1 |
| Deng, Y | 1 |
| Loo, S | 1 |
| Dziura, J | 1 |
| McDougle, CJ | 1 |
| Emslie, GJ | 1 |
| Black, BT | 1 |
| Soden, SE | 1 |
| Kearns, GL | 1 |
| Jones, BL | 1 |
| Shin, DM | 1 |
| Korada, S | 1 |
| Raballo, R | 1 |
| Shashikant, CS | 1 |
| Simeone, A | 1 |
| Taylor, JR | 1 |
| Vaccarino, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center, Open Label, Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder[NCT03337646] | Phase 4 | 48 participants (Actual) | Interventional | 2018-09-26 | Active, not recruiting | ||
| Efficacy of Pharmacologic Management of ADHD in Children and Youth With Autism Spectrum Disorder[NCT05916339] | Phase 4 | 500 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for guanfacine and Hyperactivity, Motor
| Article | Year |
|---|---|
Clinical and Pharmacologic Considerations for Guanfacine Use in Very Young Children.
Topics: Adrenergic alpha-2 Receptor Agonists; Attention Deficit Disorder with Hyperactivity; Child, Preschoo | 2016 |
1 trial available for guanfacine and Hyperactivity, Motor
| Article | Year |
|---|---|
Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Autism Spectrum Disorder; Child; Child, Preschool; | 2015 |
Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Autism Spectrum Disorder; Child; Child, Preschool; | 2015 |
Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Autism Spectrum Disorder; Child; Child, Preschool; | 2015 |
Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Autism Spectrum Disorder; Child; Child, Preschool; | 2015 |
2 other studies available for guanfacine and Hyperactivity, Motor
| Article | Year |
|---|---|
Pediatric Psychopharmacology Trials: Beyond Efficacy.
Topics: Adrenergic alpha-2 Receptor Agonists; Autism Spectrum Disorder; Delayed-Action Preparations; Female; | 2015 |
Loss of glutamatergic pyramidal neurons in frontal and temporal cortex resulting from attenuation of FGFR1 signaling is associated with spontaneous hyperactivity in mice.
Topics: Adrenergic alpha-Agonists; Amphetamine; Animals; Cell Differentiation; Cell Division; Frontal Lobe; | 2004 |